echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > [quick news] on July 3, 2018, baloxavir marboxil, a genetically engineered influenza drug, won the FDA's priority review qualification

    [quick news] on July 3, 2018, baloxavir marboxil, a genetically engineered influenza drug, won the FDA's priority review qualification

    • Last Update: 2018-07-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Baloxavir marboxil, a genetically engineered drug for influenza, has won the FDA's priority evaluation qualification

    Pharmatimes recently reported that the US FDA will give priority to the evaluation of baloxavir marboxil, a candidate influenza drug of genetically engineered drug, for the treatment of patients aged 12 and over

    Baloxavir marboxil is an innovative single dose oral drug, its mechanism of action is aimed at influenza virus

    FDA is expected to make its approval decision by December 24, 2018

    If approved, the drug will become the first oral, single tablet antiviral drug for the treatment of influenza in the past 20 years, and also the first antiviral drug with a new mechanism of action

    Http:// be approved by the European Union according to pmlive recently reported that the European drug administration has proposed approval of two car-t drugs, including kymariah of Novartis, yescarta jointly developed by Geely and kit , maybe in the second half of this year

    At present, the two drugs have been launched in the United States, marking a new era of cancer treatment based on immunotherapy

    Although they are of great concern, they still need to solve the problems of supervision and medical reimbursement in Europe before the first few qualified patients are treated

    Http:// first graphene product certification certificate was issued by Shandong litte nanotechnology Co., Ltd., a Chinese enterprise, at the global graphene spring conference held in Dresden, Germany

    Liu Zhongfan, academician of the Chinese Academy of Sciences, received the certificate issued by the international graphene product certification center

    Industry insiders believe that the issuance of the first certificate will help regulate the upstream and downstream market of graphene products and promote the healthy and orderly development of the global graphene industry

    Http:// National Key Laboratory of traditional Chinese medicine is urgently needed Recently, at the 27th National Conference on the development of traditional Chinese medicine, experts expressed their opinions around the "strategic deployment of the construction of scientific and technological innovation system of traditional Chinese medicine in line with the characteristics of traditional Chinese medicine"

    Huang Luqi, academician of Chinese Academy of engineering, appealed that the national level scientific and technological innovation base of traditional Chinese medicine should be further improved, especially the National Key Laboratory of the subject should be broken through, and we should do a good job in the science and technology of traditional Chinese medicine based on ourselves Innovation system planning and top-level design

    Http:// Div = - 1 Ningbo Research Institute of Zhejiang University was established, Yang Canjun was appointed as the president recently, Zhejiang University issued a document to establish Ningbo Research Institute of Zhejiang University, and Professor Yang Canjun, the national leader of science and technology innovation in the "ten thousand talents plan" was appointed as the president

    This marks another important step in the construction of Ningbo "five in one" campus of Zhejiang University

    In order to give full play to the advantages of "double first-class" top universities of Zhejiang University and "famous city" of Ningbo, Zhejiang University decided to build a high-level, innovative and International Ningbo Research Institute at a high starting point in Ningbo
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.